Appropriate Use of Drug Testing in Clinical Addiction Medicine
The DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.
Abstract
Biological drug testing is a tool that provides information about an individual's recent substance use. Like any tool, its value depends on using it correctly; that is, on selecting the right test for the right person at the right time. This document is intended to clarify appropriate clinical use of drug testing in addiction medicine and aid providers in their decisions about drug testing for the identification, diagnosis, treatment, and recovery of patients with, or at risk for, addiction. The RAND Corporation (RAND)/University of California, Los Angeles (UCLA) Appropriateness Method (RAM) process for combining scientific evidence with the collective judgment of experts was used to identify appropriate clinical practices and highlight areas where research is needed. Although consensus panels and expert groups have offered guidance on the use of drug testing for patients with addiction, very few addressed considerations for patients across settings and in different levels of care. This document will focus primarily on patients in addiction treatment and recovery, where drug testing is used to assess patients for a substance use disorder, monitor the effectiveness of a treatment plan, and support recovery. Inasmuch as the scope includes the recognition of addiction, which often occurs in general healthcare settings, selected special populations at risk for addiction visiting these settings are briefly included.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These immunoassays vary by lab and may only detect select agents. Some are not sensitive enough to detect therapeutic doses of BZDs, and performance of the tests vary depending on the manufacturer.147”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [147]
Citations
Cites
1 retracted
Barnes, M. C., & Worthy, S. L. (2015) · Journal of Opioid Management · doi:10.5055/jom.2015.0257 · Cited by 1
RetractedPreferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Danaei, G., Ding, E. L., Mozaffarian, D., Taylor, B., Rehm, J., Murray, C. J. L., & Ezzati, M. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000058 · Cited by 2,860
State of the art in hair analysis for detection of drug and alcohol abuse
Pragst, F., & Balikova, M. A. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2006.02.019 · Cited by 1,058
Diagnostic Potential of Saliva: Current State and Future Applications
Pfaffe, T., Cooper-White, J., Beyerlein, P., Kostner, K., & Punyadeera, C. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.153767 · Cited by 798
Urine Drug Screening: Practical Guide for Clinicians
Moeller, K. E., Lee, K. C., & Kissack, J. C. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.1.66 · Cited by 543
Detection times of drugs of abuse in blood, urine, and oral fluid
Verstraete, A. G. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200404000-00020 · Cited by 521
Oral fluid testing for drugs of abuse
Bosker, W. M., & Huestis, M. A. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.108670 · Cited by 378
Hjorthøj, C. R., Hjorthøj, A. R., & Nordentoft, M. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2011.11.025 · Cited by 364
False-Positive Interferences of Common Urine Drug Screen Immunoassays: A Review
Saitman, A., Park, H.-D., & Fitzgerald, R. L. (2014) · Journal of Analytical Toxicology · doi:10.1093/jat/bku075 · Cited by 334
Cited by
Crabb, D. W., Im, G. Y., Szabo, G., Mellinger, J. L., & Lucey, M. R. (2020) · Hepatology · doi:10.1002/hep.30866 · Cited by 922
“%CDT 21% (6-45) 100% (96-100) 100% (39-100) —”
The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update
(2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000633 · Cited by 412
The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
(2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000668 · Cited by 185
Crotty, K., Freedman, K. I., & Kampman, K. M. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000635 · Cited by 95
Validity of self-reported substance use: research setting versus primary health care setting
Khalili, P., Nadimi, A. E., Baradaran, H. R., Janani, L., Rahimi‐Movaghar, A., Rajabi, Z., Rahmani, A., Hojati, Z., Khalagi, K., & Motevalian, S. A. (2021) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-021-00398-3 · Cited by 97
Metadata
- Authors
- Jarvis, M., Williams, J., Hurford, M., Lindsay, D., Lincoln, P., Giles, L., Luongo, P., & Safarian, T.
- Affiliations
- American Society of Addiction Medicine (US)
- ORCID
- Williams, Jessica
- Venue
- Journal of Addiction Medicine
- Published
- 2017-05
- Volume
- 11
- Issue
- 3
- Pages
- 163-173
- ISSN
- 1932-0620 (ISSN-L)
- 1935-3227
- OpenAlex
- W2619437851
- Cited by
- 187
- References
- 182
- Citations by year
- 2026: 26 · 2025: 23 · 2024: 18 · 2023: 32 · 2022: 28 · 2021: 25 · 2020: 15 · 2019: 9 · 2018: 7 · 2017: 4
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Addiction Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- drug testing, addiction medicine, substance use disorders, addiction treatment, recovery, treatment monitoring, addiction diagnosis, RAND Appropriateness Method, expert consensus
- MeSH terms
- Addiction Medicine, Clinical Competence, Humans, Professional-Patient Relations, Substance Abuse Detection, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Appropriate Use of Drug Testing in Clinical Addiction Medicine. https://app.cochat.ai/papers/10.1097/adm.0000000000000323
- The paper
- Jarvis, M., Williams, J., Hurford, M., Lindsay, D., Lincoln, P., Giles, L., Luongo, P., & Safarian, T. (2017). Appropriate Use of Drug Testing in Clinical Addiction Medicine. Journal of Addiction Medicine. https://doi.org/10.1097/adm.0000000000000323
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.